Alnylam Pharmace. buy JPMorgan Chase & Co.
Start price
24.03.25
/
50%
€270.10
Target price
24.03.26
€302.97
Performance (%)
11.07%
Price
15:32
€300.00
Summary
This prediction is currently active. The prediction currently has a performance of 11.07%. This prediction currently runs until 24.03.26. The prediction end date can be changed by JPMorgan_Chase___Co_ at any time. JPMorgan_Chase___Co_ has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Alnylam Pharmace. | -2.165% | -2.165% |
| iShares Core DAX® | -1.764% | 2.259% |
| iShares Nasdaq 100 | -1.632% | -0.193% |
| iShares Nikkei 225® | -2.451% | 4.086% |
| iShares S&P 500 | -2.252% | -0.151% |
Comments by JPMorgan_Chase___Co_ for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. They now have a $328.00 price target on the stock, up previously from $280.00.
Ratings data for ALNY provided by MarketBeat
Stopped prediction by JPMorgan_Chase___Co_ for Alnylam Pharmace.
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€406.80
13.10.25
13.10.25
€407.06
13.10.26
13.10.26
-26.25%
15:32
15:32
